Tuesday, CEL-SCI Corp., a biotechnology company, released a letter to its shareholders informing the share holders that the company has bought another 87,600 shares of CEL-SCI in the open market. This decision was taken in lieu of the present market conditions that has pulled down the company's stock, despite recently presented excellent long-term survival data for cancer drug Multikine. Trading Markets (http://www.tradingmarkets.com/tm.site/news/BREAKING%20NEWS/284979/)